Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 6/20 | 1.00 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | FADS1 | O60427 | 2/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30296868 | 0.88 | PTGS1 (0.78) | PTGS1P2RX1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL7019203 | 0.87 | PTGS1 (0.76) | PTGS1P2RX1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL17744848 | 0.87 | PTGS1 (0.75) | PTGS1P2RX1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5666099 | 0.86 | P2RX1 (1.00) | PTGS1P2RX1FADS1RXFP1 | |
| SCHEMBL3822225 | 0.84 | PTGS1 (0.73) | PTGS1P2RX1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14113141 | 0.84 | PTGS1 (0.73) | PTGS1P2RX1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL31424184 | 0.84 | PTGS1 (1.00) | PTGS1P2RX1RXFP1 | |
| SCHEMBL29392990 | 0.84 | PTGS1 (1.00) | PTGS1P2RX1RXFP1 | |
| SCHEMBL4031509 | 0.84 | PTGS1 (1.00) | PTGS1P2RX1RXFP1 | |
| SCHEMBL2638776 | 0.83 | PTGS1 (0.70) | PTGS1SMN1; SMN2NPC1RAB9ATRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2660238-B1 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP (CA) | 2015-05-06 | — | — | EP | disclosed |
| US-8952021-B2 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP. (CA) | 2015-02-10 | — | — | US | disclosed |
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2382194-B1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP (CA) | 2014-03-12 | — | — | EP | disclosed |
| EP-2660238-A1 | Compounds for the prevention and treatment of cardiovascular disease | RESVERLOGIX CORP. (CA) | 2013-11-06 | — | — | EP | disclosed |
| US-8552009-B2 | Substituted pyrimido 4.5-d pyrimidin-4-one compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. | 2013-10-08 | — | — | US | disclosed |
| CN-101355946-B | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES INC | 2013-05-08 | — | — | CN | disclosed |
| US-20110294807-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | RESVERLOGIX CORP. (CA) | 2011-12-01 | — | — | US | disclosed |
| US-20110144135-A1 | Compounds for Modulating TRPV3 Function | HYDRA BIOSCIENCES, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7893260-B2 | Substituted quinazolin-4-one compounds for antagonizing TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20070179164-A1 | Compounds for modulating TRPV3 function | HYDRA BIOSCIENCES, INC. (US) | 2007-08-02 | — | — | US | disclosed |
| WO-2007056124-A2 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | HYDRA BIOSCIENCES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ | 2006-04-06 | — | — | US | disclosed |
| US-7002022-B2 | N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF | NOVARTIS AG (CH) | 2006-02-21 | — | — | US | disclosed |
| US-6878720-B2 | VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2004-10-07 | — | — | US | disclosed |
| CN-1152014-C | N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors | ��˹��ŵ�� | 2004-06-02 | — | — | CN | disclosed |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | ALTMANN KARL-HEINZ (CH) | 2003-04-03 | — | — | US | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155417-A1 | COMPOUNDS FOR MODULATING TRPV3 FUNCTION | TRPV3, TRPV1, TRPV4 | PTGS1 161/4885P2RX1 139/4885SMN1; SMN2 2219/4885 |
| US-20070179164-A1 | Compounds for modulating TRPV3 function | TRPV3, TRPV1, TRPV4 | PTGS1 161/4885P2RX1 139/4885SMN1; SMN2 2219/4885 |
| US-20030064992-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | PTGS1 916/4885P2RX1 1241/4885SMN1; SMN2 2782/4885 |
| US-20060074112-A1 | N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NR2E3, AXL, FLT1 | PTGS1 1126/4885P2RX1 983/4885SMN1; SMN2 2644/4885 |
| US-20110144135-A1 | Compounds for Modulating TRPV3 Function | TRPV3, TRPV1, TRPV4 | PTGS1 161/4885P2RX1 139/4885SMN1; SMN2 2219/4885 |
| US-20110294807-A1 | COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE | APOB, APOL1, LDLR | PTGS1 277/4885P2RX1 4030/4885SMN1; SMN2 3960/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | PTGS1 826/4885P2RX1 791/4885SMN1; SMN2 2935/4885 |
| US-20040198782-A1 | N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, NR2E3 | PTGS1 959/4885P2RX1 1269/4885SMN1; SMN2 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.